Business Context and Reporting Period
This Form 8-K, dated March 19, 2024, is filed by Graphite Bio, Inc. (the "Company") regarding the consummation of its previously announced merger with LENZ Therapeutics, Inc. ("LENZ"). The filing details the approval of a reverse stock split and a corporate name change to "LENZ Therapeutics, Inc." effective March 21, 2024.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on corporate governance actions related to the merger transaction.
Material Changes
- Stockholder Approval: On March 14, 2024, stockholders approved a reverse stock split and a name change.
- Reverse Stock Split: A 1-for-7 reverse stock split will be effected on March 21, 2024, at 4:01 p.m. Eastern Time. No fractional shares will be issued; cash will be paid in lieu of fractional shares based on fair value.
- Name Change: The Company will change its name from "Graphite Bio, Inc." to "LENZ Therapeutics, Inc."
- Trading Symbol: Common stock will commence trading under the new ticker symbol "LENZ" on March 22, 2024, with a new CUSIP number (52635N103).
- Equity Adjustments: Proportionate adjustments will be made to outstanding equity awards under the 2020 and 2021 Stock Option and Incentive Plans.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the merger's completion, the combined company's cash position, and future clinical development timelines. Management notes that actual results may differ materially due to risks including the failure to satisfy closing conditions. The document explicitly disclaims any obligation to update these forward-looking statements. Specific guidance on revenue or operational targets is not provided in this text.
Investor Verification Checklist
- Confirm the effective time of the reverse stock split and name change (March 21, 2024, 4:01 p.m. ET).
- Verify the new ticker symbol ("LENZ") and CUSIP number (52635N103) for trading commencing March 22, 2024.
- Review the treatment of fractional shares (cash payment in lieu of issuance).
- Check the impact of the 1-for-7 split on existing equity awards and exercise prices.
- Refer to the Form 10-K (filed Feb 27, 2024) and Form 424(b)(3) (filed Feb 13, 2024) for detailed risk factors and financial data not included in this 8-K.